Drug Trial Radar · NCT06396416
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 26, 2024
Primary completion
Sep 30, 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Western University, CanadaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's; Queen Elizabeth II Health Sciences Centre; Unity Health Toronto
- First posted
- May 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Conditions
- Obesity
- Chronic Kidney Disease
Interventions
SemaglutideDrug
Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Virtual Weight Management CoachingBehavioral
Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of RecruitmentTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
London Health Sciences Centre
London, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.